Skip to content
Back to news

Our R&D Institute in Paris-Saclay opens its doors to patients

Six representatives from four patient organizations visited our Institute in Paris-Saclay: Alliance du Cœur, Ellye, AVEC (Association Vie Et Cœur) and Espoir Pancréas.

The program was tailor-made to showcase our patient involvement in R&D programs, the work of the Institute’s researchers, and our integrated CSR approach at the Saclay site. Guillaume Molinier, from Alliance du Cœur, emphasized the importance of visiting sites and meeting employees. “Meeting researchers means getting to know the people who work day in and day out to discover therapeutic solutions. The human element behind the company is essential,” he said.

Did you know ?

In 2023, our Servier Research & Development Institute opened its doors at the Paris-Saclay interdisciplinary innovation cluster. In a few years’ time, this scientific hub of excellence will be home to almost 25% of France’s scientific research.

Patients also enjoyed the many opportunities for interaction, including educational sessions on the Group’s strategy, with a special focus on oncology and rare diseases. Annie Charrette and Philippe Francois-Steininger from Espoir Pancréas were particularly impressed: “We had the opportunity to learn more about Servier R&D. Paris-Saclay’s scientific community is a real asset, not only for G5 Santé, but also for France as a whole.” 

These views are shared by our teams :

Our R&D Institute in Paris-Saclay: Driving today’s research to reinvent tomorrow’s healthcare

G5 santé is a think-tank bringing together the heads of France’s leading healthcare and life sciences companies (bioMérieux, Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi, Servier and Théa). These companies have chosen France as a strategic base for their international development and have made R&D and production their top priorities. For the third consecutive year, from March 11 to April 3, 2024, the eight G5 Santé companies opened the doors of a dozen production and research sites to representatives of partner patient organizations, with the aim of continuing a lasting and fruitful dialogue with healthcare users.

Speeding up research and pioneering new therapeutic solutions 

Our teams strive every day to discover and develop medicines in the areas where patients’ needs are greatest.